Shire Submits Vyvanse sNDA For Adult ADHD
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to announce data from a Phase III trial in adults in the fourth quarter.
You may also be interested in...
No Deficit To Shire’s Top Line In ADHD
New product sales drive firm’s revenue growth, including an impressive market grab by attention deficit/hyperactivity disorder product Vyvanse.
No Deficit To Shire’s Top Line In ADHD
New product sales drive firm’s revenue growth, including an impressive market grab by attention deficit/hyperactivity disorder product Vyvanse.
Shire Divests Eight “Non-Core” Products To Almirall For $213 Million
Deal, which includes Solaraze and Vaniqa, is in line with U.K. firm's strategy of focusing on development of specialty products.